Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
62.79
-0.12 (-0.19%)
At close: Oct 12, 2026, 4:00 PM EDT
61.54
-1.25 (-1.99%)
After-hours: Oct 12, 2026, 7:30 PM EDT
Cytokinetics Market Cap
Cytokinetics has a market cap or net worth of $8.73 billion as of October 12, 2026. It is the 2,413th most valuable company in the world and the 836th biggest in the United States. Its market cap has increased by 21.51% in one year.
Market Cap
8.73B
Enterprise Value
8.99B
1-Year Change
21.51%
Global Rank
Country Rank
#836 United States
Category
ChartMarket Cap Chart
Since April 30, 2004, Cytokinetics's market cap has increased from $419.30M to $8.73B, an increase of 1,981.87%. That is a compound annual growth rate of 14.47%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 12, 2026 | 8.73B | 12.36% |
| Dec 31, 2025 | 7.77B | 39.94% |
| Dec 31, 2024 | 5.55B | -32.19% |
| Dec 29, 2023 | 8.19B | 88.80% |
| Dec 30, 2022 | 4.34B | 13.41% |
| Dec 31, 2021 | 3.82B | 159.95% |
| Dec 31, 2020 | 1.47B | 134.61% |
| Dec 31, 2019 | 626.90M | 81.29% |
| Dec 31, 2018 | 345.80M | -21.27% |
| Dec 29, 2017 | 439.20M | -10.79% |
| Dec 30, 2016 | 492.30M | 21.17% |
| Dec 31, 2015 | 406.30M | 38.57% |
| Dec 31, 2014 | 293.20M | 52.87% |
| Dec 31, 2013 | 191.80M | 104.04% |
| Dec 31, 2012 | 94.00M | 35.45% |
| Dec 30, 2011 | 69.40M | -49.60% |
| Dec 31, 2010 | 137.70M | -22.34% |
| Dec 31, 2009 | 177.30M | 25.83% |
| Dec 31, 2008 | 140.90M | -39.40% |
| Dec 31, 2007 | 232.50M | -17.84% |
| Dec 29, 2006 | 283.00M | 51.01% |
| Dec 30, 2005 | 187.40M | -35.49% |
| Dec 31, 2004 | 290.50M | -30.72% |
| Apr 30, 2004 | 419.30M | - |
View and export this data all the way back to 2004. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Twist Bioscience | 10.02B |
| Krystal Biotech | 9.82B |
| Kymera Therapeutics | 9.35B |
| Protagonist Therapeutics | 9.30B |
| Arrowhead Pharmaceuticals | 8.86B |
| Axsome Therapeutics | 8.82B |
| Caris Life Sciences | 8.39B |
| Spyre Therapeutics | 8.01B |